Synchron BCI Pivotal Trial: Endpoint and Reimbursement Path

Synchron’s $200 million Series D, closed November 6, 2025, committed the company to one specific deliverable: a pivotal trial in 2026. The company has navigated a decade of neuroengineering to get here — the endovascular Stentrode approach, the SWITCH and COMMAND feasibility studies, FDA IDE approval, Apple HID integration, and a Cognitive AI division. What happens next depends not on whether the Stentrode works. The COMMAND data are already in. The outcome turns on a single design decision: what the trial designates as its primary endpoint.

That choice — functional independence versus communication-rate metrics — will shape not just Synchron’s PMA application but the entire commercial infrastructure of implantable BCIs. CMS does not simply accept FDA approval as sufficient for coverage. It evaluates clinical evidence on its own framework, using criteria that are specific to the claimed therapeutic benefit. The endpoint that wins FDA approval and the endpoint that unlocks BCI reimbursement are not automatically the same endpoint. The difference between “approved with BCI reimbursement” and “approved but unprofitable” is a methodological decision that needs to be made before the first pivotal patient is enrolled.

The Two Candidate Endpoints and What They Measure

Synchron’s Stentrode is designed for patients with severe motor paralysis — primarily ALS but also spinal cord injury and other causes of quadriplegia — who have lost the ability to communicate or interact with digital devices. The device records motor intent from the superior sagittal sinus and translates it into digital outputs: cursor movement, text input, device control.

Two endpoint frameworks have been used or proposed across the implantable BCI literature.

Communication-rate metrics measure how efficiently a user can transmit information through the device. The standard metric is words per minute (WPM), often combined with character accuracy. Neuralink’s PRIME trial reports WPM as its primary public performance figure — 13.7 WPM mean, with some participants reaching 40 WPM on virtual keyboard tasks. WPM is intuitive and measurable. It also maps poorly onto what CMS evaluates when deciding whether a device warrants coverage under the durable medical equipment (DME) benefit category.

Functional independence measures assess a patient’s ability to perform activities of daily living with reduced caregiver assistance. The canonical instrument is the Functional Independence Measure (FIM) — an 18-item scale that scores motor and cognitive functional capacity, with a maximum score of 126. The FIM captures toileting, grooming, bladder management, locomotion, comprehension, memory, and social interaction. A BCI that improves FIM score — even modestly — provides documentable evidence that a device reduces the care burden for a patient who would otherwise require 24-hour attendant support.

The distinction matters because BCI reimbursement decisions for assistive and augmentative devices have historically turned on functional benefit, not technical performance. The agency’s Local Coverage Determinations (LCDs) for augmentative and alternative communication (AAC) devices — the closest current coverage analogue to a communication BCI — require documentation of the patient’s inability to use other less-costly alternatives, the expected functional benefit, and that the device is reasonable and necessary for the patient’s condition. A high WPM score does not, by itself, satisfy these criteria. A demonstrated improvement in communication-dependent activities of daily living does.

The CMS Coverage Precedent Problem for BCI Reimbursement

There is no CMS coverage determination for implantable BCIs. Synchron will be navigating terrain for which no roadmap exists.

The nearest analogues are instructive for what they omit. AAC devices (speech-generating devices covered under the Medicare DME benefit) require prior authorization and physician documentation, but the coverage framework was designed for external devices — tablets, switches, eye-gaze systems. The implantable BCI category does not fit cleanly into any existing HCPCS billing code — the closest analogues, the E2500–E2599 speech-generating device series (e.g., E2510 for synthesized-speech devices), were written for external hardware, not implanted neural interfaces. Synchron — and any BCI company that follows — will need either a new code or a successful coverage-by-analogy argument.

The coding pathway has two stages: first, a Category III CPT code for the implantation procedure (temporary, used for data collection); then, a Category I CPT code once the procedure reaches “widespread clinical use.” CMS sets payment rates for Category I codes using RVU calculations. Until a Category I CPT code exists and CMS establishes a National Coverage Determination (NCD) or an acceptable regional LCD pathway, hospitals implanting an FDA-cleared BCI face a billing problem. Procedure-only payment without device reimbursement is economically unsustainable for centers building an implantation program.

The timeline for moving from PMA approval to a functioning NCD has ranged from two to seven years for other Class III neurology devices. Deep brain stimulation (DBS) for Parkinson’s disease — a useful precedent given the surgical complexity overlap — received its first PMA approval in 1997 and Medicare coverage by 2003. Spinal cord stimulation devices have iterated through multiple NCD amendments. In each case, the quality of the clinical evidence presented at PMA — and specifically whether that evidence documented benefit in terms CMS recognized as clinically meaningful — affected the speed and breadth of coverage determination.

This is why endpoint choice is not just a regulatory question. It is a BCI reimbursement pre-positioning decision.

Why Functional Independence Endpoints Are Commercially Stronger

A pivotal trial designed around functional independence measures produces evidence that speaks directly to the CMS coverage decision framework.

The FIM and its successors (the AM-PAC, WHODAS 2.0, and the Patient-Reported Impact of Assistive Devices scale, PIADS) are instruments that CMS evaluators and Medicare Administrative Contractors already use in related coverage determinations. An NDA or PMA submission that documents: (a) statistically significant FIM improvement at 12 months; (b) reduction in hours of daily caregiver assistance; and (c) maintenance of effect at 24 months, gives a coverage determination reviewer specific numbers to write into an LCD.

The counter-argument for communication-rate endpoints is that they are more sensitive and more measurable within a feasibility-trial sample size. FIM improvements in a severe paralysis population are hard to achieve — a device that enables text communication does not necessarily move the needle on toileting or locomotion, which are high-weight FIM domains. The risk of a functional independence primary endpoint is a trial that demonstrates real communicative utility but technically misses the primary endpoint on a scale designed for broader physical function.

This is the analytical tension Synchron’s clinical design team is navigating. A composite endpoint — one that combines a communication-specific FIM subdomain (the FIM Comprehension and Expression subscales) with a WPM-anchored communication-rate threshold — could thread this needle. The challenge is that composite endpoints with heterogeneous components are more difficult for both FDA reviewers and CMS economists to interpret. ClinicalTrials.gov shows Synchron’s current registered studies do not yet list a pivotal trial — indicating, as of this writing, that the design is still being finalized.

Neuralink’s Endpoint Choices: A Useful Comparison

Neuralink’s PRIME study designates safety as the primary endpoint — adverse events and device-related complications over 12 months — with WPM and cursor-control accuracy as secondary efficacy endpoints. The PRIME study protocol on ClinicalTrials.gov specifies primary completion of 12 months safety data. This is consistent with a first-in-human feasibility design, not a pivotal design. Neuralink has not announced a pivotal trial protocol.

Neuralink’s WPM framing is effective for public communication and investor narrative. It is less effective for CMS documentation. When the company reaches a pivotal phase — which its Series E financing timeline implies is 2027–2028 at earliest — it will face the same endpoint question Synchron is resolving now. Synchron’s choice will therefore function as a field-wide precedent: whichever framework the first PMA applicant uses will be cited by every subsequent applicant and by CMS reviewers evaluating those applications.

There is an additional architectural wrinkle. Neuralink’s integration of Grok (xAI’s LLM) into its decoding stack means its reported WPM figures already include an AI language model assist — the system surfaces word completions and plausible responses, reducing effective character-level error rates to below 10% in closed-vocabulary tasks. MIT Technology Review covered the Grok integration in May 2025.

Synchron’s Cognitive AI division is doing similar work. The endpoint question for the field then becomes: is it the electrode array’s performance being measured, or the system’s performance? For FDA, the system-level performance is what matters for clearance. For CMS, the question will be whether the AI-augmented output constitutes a medical device or a consumer software service — a distinction with significant implications for which coverage bucket applies.

The PMA Pathway and Sham Control Design

Synchron is pursuing PMA, not De Novo or 510(k). PMA is the highest-burden FDA approval pathway, reserved for Class III devices — those that present the greatest potential risk and for which no substantially equivalent predicate exists. An implantable endovascular neural interface has no predicate. PMA requires valid scientific evidence that the device is safe and effective for its intended use, and that evidence must come from well-controlled clinical trials.

The sham control question in BCI trials is analytically uncomfortable. A true sham-controlled trial for an implantable device requires patients to undergo the same implantation procedure without the device being activated — or, in a surgical sham, to undergo a procedure with no device implanted at all. Neither option is straightforward for an endovascular procedure in ALS patients. The FDA has indicated willingness in similar surgical device trials to accept pre-post within-patient designs with carefully controlled co-intervention monitoring when a sham arm is not ethically or practically feasible.

Synchron’s COMMAND design used a within-subject control: each patient’s baseline communication performance was documented before implantation and compared to post-implantation performance at 3, 6, and 12 months. The pivotal design will likely require either an expanded within-subject comparator, a waitlist control arm (patients receiving standard of care pending implantation), or a crossover design. The choice of comparator affects both the sample size calculation and the evidentiary weight assigned to the data in the PMA submission. FDA’s neurological device guidance documents offer the applicable framework for these control arm decisions, though no BCI-specific guidance exists yet.

The Economics of Getting BCI Reimbursement Right

The commercial case for a correctly designed pivotal trial is not abstract. Securing clear BCI reimbursement is essential, parallel to how clinical endpoint design determines commercial adoption across novel oncology cell therapies and novel biotech drug discovery pipelines; without that pathway, a device is commercially inert for the hospital market.

Consider the economics: a Stentrode implantation requires an interventional neuroradiology suite, an experienced catheter-based neurosurgeon, a dedicated device programmer for training, and ongoing remote monitoring. The total procedure and first-year management cost — excluding device cost — has been estimated at $30,000 to $50,000.

If the device itself is priced at $40,000 to $80,000, total first-year per-patient cost lands between $70,000 and $130,000. (All three figures are author estimates based on comparable neuromodulation procedures; no Synchron list price exists.) Without reimbursement, that expenditure falls on the patient or insurer through out-of-pocket billing — a mechanism that works for a small subset of privately insured patients and almost no Medicare beneficiaries.

Stat
$70K–$130K
Estimated first-year per-patient cost of a Stentrode implantation and device — the figure BCI reimbursement determines who actually pays.

The ALS population — Synchron’s core addressable market — skews heavily toward Medicare and Medicare Advantage. The average age of ALS onset is approximately 55 years; the disease typically progresses to severe dysphagia and motor paralysis within two to five years of onset. A substantial fraction of patients are Medicare-eligible by the time they reach the functional status that would qualify them for a BCI. If CMS does not cover the device, the addressable paying market is a small, affluent, working-age subset. The pivotal trial endpoint choice is, in that sense, also a market-size decision.

A functioning reimbursement pathway at, say, $50,000 per patient annually — consistent with comparable advanced neuromodulation approvals — would make the BCI addressable by roughly 30,000 new ALS patients diagnosed in the United States each year, plus the estimated 290,000 living with spinal cord injury who might qualify. Even at 1–2% penetration in the first three years post-approval, that is a commercially viable volume. Getting there requires CMS coverage. Getting CMS coverage requires clinical evidence designed for that purpose from the start.

Key takeaways

  • No CMS coverage determination exists yet for implantable BCIs — Synchron’s pivotal trial design will set the field-wide precedent.
  • Functional independence endpoints (FIM) map onto what CMS actually evaluates for coverage; communication-rate metrics (WPM) do not.
  • Neuralink’s safety-first PRIME design defers this question; Synchron’s PMA submission will be the first real test.
  • Without a BCI reimbursement pathway, the addressable market shrinks to a small, affluent, working-age, privately-insured subset.

What to Watch

The pivotal trial design announcement — expected at a major neuroscience conference such as the Society for Neuroscience annual meeting or AAN, or via a peer-reviewed publication in NEJM or Nature Medicine — is the single most important forthcoming BCI disclosure. Specifically: does the protocol specify functional independence as the primary endpoint, WPM-based communication rate, or a composite? Does the comparator arm consist of a waitlist control or a pre-post within-subject design? And does the statistical analysis plan pre-specify a CMS-mappable secondary endpoint, even if the FDA primary endpoint is structured differently?

The answers will define the evidentiary floor for BCI reimbursement — not just for Synchron, but for every company that follows.

This article was produced with AI assistance and reviewed by the editorial team.

—

Arjun Mehta

Arjun Mehta

Arjun Mehta covers AI infrastructure, semiconductor manufacturing, and the science-to-commercialization pipeline for Next Waves Insight. His reporting focuses on the technical and economic mechanics behind emerging technology — from chip fabrication constraints to the regulatory and funding pathways that determine which breakthroughs actually reach production. He has covered the technology sector for several years, with a focus on connecting primary research and hardware development to their downstream industry impact.

1 thought on “Synchron BCI Pivotal Trial: Endpoint and Reimbursement Path”

Leave a Comment